Skip to main content
Quest Diagnostics

COVID-19, flu, and RSV combination testing

Know more, sooner, with respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial, so treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Distinguishes between SARS-CoV-2 (COVID-19), influenza A and B, RSV, and other respiratory pathogens with just 1 swab

Eliminates the need for multiple tests or patient visits—helping to speed up the time to a diagnosis

Reduces diagnostic uncertainty and can help guide early treatment management decisions4

Highly sensitive and specific, nucleic acid amplification tests (also known as molecular tests) capable of detecting 1 or more viruses are the diagnostic “gold standard”4

Combination testing options from Quest Diagnostics

Other respiratory testing options

Panel components may be ordered separately.

PSC testing availability

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is available for collection at Quest Patient Service Centers (PSCs) for patients with mild symptoms.
Find a Quest PSC near you
39992-50-50.jpg

COVID-19 testing statements

  • The Quest Diagnostics molecular test, the other authorized molecular tests (together the “molecular tests”), the COVID/Flu molecular test, the COVID/Flu/RSV test, and the antibody test (together “the tests”) have not been FDA cleared or approved;
  • The tests have been authorized by FDA under an EUA for use by authorized laboratories;
  • The molecular tests have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for the detection of nucleic acid from SARS CoV-2, not for any other viruses or pathogens;
  • The COVID/Flu molecular test and self-collection kit have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for as an aid in detection of nucleic acid from SARS-CoV-2 and influenza A virus and influenza B virus, not for any other viruses or pathogens;
  • The COVID/Flu/RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
  • The antibody test has been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and,
  • The tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


References

  1. 1CDC. Testing for COVID-19. Updated June 25, 2024. Accessed August 23, 2024. https://www.cdc.gov/covid/testing/index.html
  2. CDC. Weekly US Influenza Surveillance Report. Updated August 16, 2024. Accessed August 23, 2024. https://www.cdc.gov/flu/weekly/index.htm
  3. CDC. Clinical Overview of RSV. Updated July 3, 2024. Accessed August 23, 2024. https://www.cdc.gov/rsv/hcp/clinical-overview/index.html
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508

Questions?

For more information on our combination testing solutions, or to set up a Quest account, connect with a Quest representative.

Contact us

COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.